AGTC to Participate at Upcoming Virtual Investor Conferences
Wells Fargo Virtual Healthcare Conference( September 9-10, 2020) Sue Washer, President & Chief Executive Officer, will participate in a fireside chat at 9:20 a.m. ETon Thursday, September 10, 2020. H.C. Wainwright22nd Annual Global Investment Virtual Conference( September 14-16, 2020)
AGTC management will participate in investor 1x1 meetings on
Monday, September 14, 2020and Tuesday, September 15, 2020. Cantor Fitzgerald Virtual Global Healthcare Conference2020 ( September 15-17, 2020) Ms. Washerwill participate in a fireside chat at 2:40 p.m. ETon Wednesday, September 16, 2020.
A live audio webcast of the presentation at the Wells Fargo and
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. The Company’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its pre-clinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.
Chief Financial Officer
T: (617) 843-5728
Chief Business Officer
T: (617) 413-2754
Source: Applied Genetic Technologies Corporation